VolitionRx Ltd (VNRX) company profile
Close on Nov 17, 2026Market cap $2.58MP/E –Yield –
About VolitionRx
In Vitro & In Vivo Diagnostic Substances, SIC 2835
VolitionRx Limited is a multi-national epigenetics company that develops blood-based tests to detect and monitor cancer and diseases associated with NETosis, such as sepsis. Its patented technologies, including Nu.Q and Capture-PCR/Capture-Seq, analyze circulating nucleosomes, transcription factors, and tumor-derived DNA in the blood to identify disease changes at early stages. The company's key product pillars encompass Nu.Q Vet for canine cancer screening and companion animal diagnostics, Nu.Q NETs for conditions linked to NETosis, Nu.Q Discover for nucleosome profiling in drug research, and Nu.Q Cancer for human oncology detection and monitoring. Volition serves veterinarians, pet owners, academic institutions, diagnostic providers, and pharmaceutical researchers.
The company operates a purpose-built 17,000 square foot laboratory and 10,000 square foot manufacturing facility in Gembloux, Belgium, alongside an innovation lab and offices in California, London, and Nevada. It employs 75 full-time equivalent staff members, and its canine cancer test is available across more than twenty countries. VolitionRx maintains its principal executive office in Henderson, Nevada.
Summary of the business section of VolitionRx's latest annual report, written by StockData.
Company profile
Company
- Legal name
- VolitionRx Ltd
- Founded
- 1998
- Headquarters
- Henderson, NV
- Address
- 1489 West Warm Springs Road, Suite 110 89014
- Phone
- 1 (512) 774-8930
- Website
- volition.com
- Employees
- 75, Dec 31, 2025
- Industry
- In Vitro & In Vivo Diagnostic Substances
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Sadler, Gibb & Associates, LLC, Draper, UT
Stock & identifiers
- Ticker
- VNRX
- Exchange
- NYSE
- IPO date
- Mar 2, 2012
- Shares outstanding
- 14M, Aug 11, 2026
- Public float
- $72.91M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-20 reverse, Apr 28, 2026
- SEC CIK
- 93314
- CUSIP
- 928661206
- ISIN
- US9286612067
- FIGI
- BBG000BQWFH2
- Share class FIGI
- BBG001SDZ7B2
- EIN
- 91-1949078
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Cameron John Reynolds | President and CEO, Director | 4,157,341 |
| Ann-Louise Batchelor | Group Chief Marketing Officer | 29,257 |
| Gaetan Michel | Chief Operating Officer | 12,232 |
| Gael Forterre | Chief Commercial Officer | 18,159 |
| Nicholas Plummer | GC - Volition Diagnostics | 407,267 |
| Rodney Gerard Rootsaert | Secretary | 1,281,711 |
| Jacob Vincent Micallef | Chief Scientific Officer | 665,292 |
| Terig Hughes | Chief Financial Officer | 684,970 |
| Jasmine Kway | CEO - Singapore Volition | 429,014 |
| Salvatore Thomas Butera | CEO - Volition Veterinary | 375,203 |
| Andrew Retter | Chief Medical Officer | 146,568 |
| Guy Archibald Innes | Director | 3,317,974 |
| Ethel Rubin | Director | 252,948 |
| Kim Nguyen | Director | 336,372 |
| Timothy I. Still | Director | 1,625,458 |
| Phillip Barnes | Director | 67,368 |
| Mickie Henshall | Director | 44,206 |
| Alan Colman | Director | 257,364 |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Stock awards | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|
| Cameron Reynolds President and Chief Executive Officer | $473.94K | – | $132.57K | $31.72K | $638.23K | +15% |
| Dr. Gaetan Michel Chief Operating Officer | $178.16K | $23.30K | – | $238.16K | $439.61K | -3% |
| Dr. Salvatore Thomas Butera Chief Executive Officer, Volition Vet | $296.08K | – | $77.79K | $127.17K | $501.04K | +29% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 75 full-time equivalent (“FTE”) personnel compared to 85 as of December 31, 2024, reflecting the need to prioritize the cash utilization in our commercial and production activities.”
Corporate history
Events identified from SEC filings
See a number that looks wrong?